Pain Study
Separate Search Page
or search below
|
Home Page Pain Study |
Separate Search Page |
|
| Free Sample | Write To Karl Loren | What Is Pain? |
Increased Heart Disease and Death
Our "Estimated Annual Cost of Crohn's/Annual Cost Savings From Curing Crohn's Disease (Excluding Newer and More Expensive Treatments)" totaling $3.2 billion does not take into account "revolutionary" new drugs which treat the symptoms of CD such as the new mono-clonal antibody, Remicade.
In 1999 -- the first full year of Remicade's availability -- use of Remicade dramatically increased each month. The cost of each infusion of Remicade is $1,400. Since the drug only lasts in the body for six (6) to eight (8) weeks and because this drug is not a cure, but, as with all other widely available Crohn's treatments today, treats only symptoms, multiple infusions must be done on many patients. Further, due to the dangers of this treatment, Remicade must be infused in a hospital setting under the care of a physician and numerous medical professionals, resulting in additional hospital, physician and hospital staff costs. Excluding the cost of medical care, and assuming that only one-third of Crohn's patients opt to try this new treatment, and assuming that each patient has only one infusion, this new treatment will, using the most conservative estimates, increase the total annual cost of Crohn's by an additional $190 million [rounded] (See Calculation II and Calculation III below).
If you experienced serious side effects from the use of Remicade, or a person died due to an adverse reaction while taking Remicade, there may be a claim for legal compensation.
Legal compensation claims involving a Remicade disease or death caused by Remicade are usually made by filing a Remicade claim as a court case.
All states have statutes of limitations that determine the time period allowed to file a Remicade claim. The applicable statute of limitation, or deadline to file claims, varies from state to state, and the personal injury statute of limitation deadline can be different from the wrongful death statute of limitation deadline within the same state. For example, in some states a personal injury claim must be filed within 3 years from the date the Remicade-related disease or Remicade drug interaction is diagnosed, while a wrongful death claim must be filed within 2 years from the date of a death caused by Remicade. In some states, the statutes of limitations may be as short as 1 year from the date of diagnosis or death.
Because of these varying deadlines, you should not delay seeking a law firm to provide legal advice and legal representation when there is a possible Remicade claim involving a Remicade injury or a Remicade death.
The Law Offices of Thomas J. Lamb, P.A. represents people who have suffered serious or adverse effects arising from the use of Remicade, resulting in a Remicade injury or Remicade death. We handle all Remicade claims on a contingency fee basis, which means there is no bill for legal services until after the law firm gets a settlement or verdict for the client.
If you, relatives, or friends need legal advice or legal representation for an injury or death which may have been caused by Remicade, the Law Offices of Thomas J. Lamb, P.A. is available to discuss the case, free of charge. Our toll-free number is (800) 426-9535.
Visit our Remicade Information Page >>
Remicade (infliximab) works by blocking TNF-a (tumor necrosis factor alpha), a small protein which is very important in the regulation of the immune system. An excess of TNF-a is believed to be a cause of autoimmune diseases such as rheumatoid arthritis and Crohn's Disease. When there is more TNF in the blood than the body's natural receptors can handle, the result is inflammation. Remicade is used to neutralize excess TNF and reduce inflammation. Adverse event reports involving Remicade later revealed that blocking TNF to inhibit rheumatoid arthritis and Crohn's Disease allows other diseases to develop, such as tuberculosis, histoplasmosis, listeriosis, and pneumocystosis.
Remicade is a treatment for inflammation
associated with certain autoimmune disorders, including Crohn's disease and
rheumatoid arthritis. The manufacturer recently stopped tests evaluating whether
Remicade can be used to treat congestive heart failure after reports of
hospitalization and death in Remicade users.
Johnson & Johnson recently announced it has stopped trials evaluating Remicade,
citing a higher death rate in heart patients using the arthritis drug than is
those tested with a placebo.
Johnson & Johnson announced that "the results demonstrated no improvements in
patients' clinical status and showed higher incidence of mortality and
hospitalization for worsening heart failure in Remicade-treated patients."
A popular arthritis drug used by 170,000 patients worldwide, Remicade works by
blocking an inflammation-causing protein called tumor necrosis factor (TNF).
Johnson & Johnson recently announced that tests have "failed to demonstrate that
agents that bind TNF can improve the clinical course in these patients."
The recent announcements by Johnson & Johnson follow a banner third quarter in
2001, during which time sales of Remicade soared 129% to $209 million.
xx
|
I promise to answer your message -- click here to send me a personal message
|
You can reach Karl Loren at www.PainStudy.com by mail at 1831 N. Bel Aire Drive, Burbank, CA 91504. Within the US and Canada, use the toll free number: (800) 523-4521, the local number: (818) 558-1799, the FAX: (818) 558-7299, eMail to karl@painstudy.com
Copyright © May 20, 2008 6:26 AM by Karl Loren on behalf of Vibrant Life, ALL RIGHTS RESERVED. Permission is granted for non-commercial downloading, copying, distribution or redistribution on two conditions: One, that some form of copyright notice is included in every copy distributed or copied, showing the copyright belonging to Vibrant Life, Burbank, CA, at www.oralchelation.com . The second condition is that the material is not to be used for any purpose contrary to the purposes and objectives of this site. This permission does not extend to materials on this site which are copyrighted by others.